Fragile X Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Fragile X syndrome is caused by a change in a gene called FMR1. It occurs both in males and females. The symptoms of Fragile X Syndrome include delay in crawling, walking, or twisting, hyperactive or impulsive behavior, speech or language delay, and intellectual disability.
The Fragile X Syndrome pipeline market research report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects.
Key Targets in the Fragile X Syndrome Pipeline Products Market
The key targets in the Fragile X Syndrome pipeline products market are Synaptic Functional Regulator FMR1, Glutamate Ionotropic Receptor NMDA Type Subunit, Metabotropic Glutamate Receptor 5, 70 kDa Ribosomal Protein S6 Kinase, Cannabinoid Receptor 1, Glutamate Ionotropic Receptor AMPA Type Subunit, Potassium Voltage Gated Channel Subfamily C Member 1, Purinergic Receptor P2X, Purinergic Receptor P2Y, Sigma Non Opioid Intracellular Receptor 1, and others
Fragile X Syndrome Pipeline Products Market Analysis by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Fragile X Syndrome Pipeline Products Market
The key mechanisms of action in the Fragile X Syndrome pipeline products market are Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Metabotropic Glutamate Receptor 5 Antagonist, 70 kDa Ribosomal Protein S6 Kinase Inhibitor, Cannabinoid Receptor 1 Agonist, Glutamate Ionotropic Receptor AMPA Type Subunit Agonist, Potassium Voltage Gated Channel Subfamily C Member 1 Activator, Purinergic Receptor P2X Antagonist, Purinergic Receptor P2Y Antagonist, Sigma Non Opioid Intracellular Receptor 1 Agonist, Synaptic Functional Regulator FMR1 Activator, and others.
Fragile X Syndrome Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights, download a free report sample
Key Routes of Administration in the Fragile X Syndrome Pipeline Products Market
The key routes of administration in the Fragile X Syndrome pipeline products market are oral, intravenous, intrathecal, nasal, parenteral, and transdermal.
Fragile X Syndrome Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Fragile X Syndrome Pipeline Products Market
The key molecule types in the Fragile X Syndrome pipeline products market are small molecule, gene therapy, antisense oligonucleotide, recombinant peptide, and synthetic peptide.
Fragile X Syndrome Pipeline Products Market Analysis by Molecule Types
For more molecule type insights, download a free report sample
Major Companies in the Fragile X Syndrome Pipeline Products Market
Some of the major companies in the Fragile X Syndrome pipeline products market are Connecta Therapeutics SL, Healx Ltd, Autifony Therapeutics Ltd, Confluence Pharmaceuticals LLC, Epigen Biosciences Inc, Neuren Pharmaceuticals Ltd, Paxmedica Inc, RespireRx Pharmaceuticals Inc, Actinogen Medical Ltd, and Allos Pharma Inc.
Fragile X Syndrome Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Fragile X Syndrome Pipeline Products Market Report Overview
Key Targets | Synaptic Functional Regulator FMR1, Glutamate Ionotropic Receptor NMDA Type Subunit, Metabotropic Glutamate Receptor 5, 70 kDa Ribosomal Protein S6 Kinase, Cannabinoid Receptor 1, Glutamate Ionotropic Receptor AMPA Type Subunit, Potassium Voltage Gated Channel Subfamily C Member 1, Purinergic Receptor P2X, Purinergic Receptor P2Y, Sigma Non Opioid Intracellular Receptor 1, and Others |
Key Mechanisms of Action | Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Metabotropic Glutamate Receptor 5 Antagonist, 70 kDa Ribosomal Protein S6 Kinase Inhibitor, Cannabinoid Receptor 1 Agonist, Glutamate Ionotropic Receptor AMPA Type Subunit Agonist, Potassium Voltage Gated Channel Subfamily C Member 1 Activator, Purinergic Receptor P2X Antagonist, Purinergic Receptor P2Y Antagonist, Sigma Non Opioid Intracellular Receptor 1 Agonist, Synaptic Functional Regulator FMR1 Activator, and Others |
Key Routes of Administration | Oral, Intravenous, Intrathecal, Nasal, Parenteral, and Transdermal |
Key Molecule Type | Small Molecule, Gene Therapy, Antisense Oligonucleotide, Recombinant Peptide, and Synthetic Peptide |
Major Companies | Connecta Therapeutics SL, Healx Ltd, Autifony Therapeutics Ltd, Confluence Pharmaceuticals LLC, Epigen Biosciences Inc, Neuren Pharmaceuticals Ltd, Paxmedica Inc, RespireRx Pharmaceuticals Inc, Actinogen Medical Ltd, and Allos Pharma Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fragile X Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fragile X Syndrome (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fragile X Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Allos Pharma Inc
Anavex Life Sciences Corp
Anima Biotech Inc
Astellas Pharma Inc
Autifony Therapeutics Ltd
Avekshan LLC
Cognosetta Inc
Confluence Pharmaceuticals LLC
Connecta Therapeutics SL
DRI Biosciences Corp
Epigen Biosciences Inc
GEXVal Inc
GSK plc
Healx Ltd
Hua Medicine Shanghai Ltd
Jazz Pharmaceuticals Plc
Lysogene SAS
Neuren Pharmaceuticals Ltd
Neurochlore
NeuroNascent Inc
Novartis AG
Paxmedica Inc
Pilz Bioscience Corp
Prilenia Therapeutics Development Ltd
Prous Institute for Biomedical Research SA
Puretech Health Plc
Quris Technologies Ltd
Recursion Pharmaceuticals Inc
RespireRx Pharmaceuticals Inc
Sentinel Oncology Ltd
Synaptogenix Inc
Takeda Pharmaceutical Co Ltd
Taysha Gene Therapies Inc
Tetra Therapeutics
Triplet Therapeutics Inc
Zynerba Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Fragile X Syndrome products market?
The key targets in the Fragile X Syndrome pipeline products market are Synaptic Functional Regulator FMR1, Glutamate Ionotropic Receptor NMDA Type Subunit, Metabotropic Glutamate Receptor 5, 70 kDa Ribosomal Protein S6 Kinase, Cannabinoid Receptor 1, Glutamate Ionotropic Receptor AMPA Type Subunit, Potassium Voltage Gated Channel Subfamily C Member 1, Purinergic Receptor P2X, Purinergic Receptor P2Y, Sigma Non Opioid Intracellular Receptor 1, and others.
-
What are the key mechanisms of action in the Fragile X Syndrome pipeline products market?
The key mechanisms of action in the Fragile X Syndrome pipeline products market are Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, Metabotropic Glutamate Receptor 5 Antagonist, 70 kDa Ribosomal Protein S6 Kinase Inhibitor, Cannabinoid Receptor 1 Agonist, Glutamate Ionotropic Receptor AMPA Type Subunit Agonist, Potassium Voltage Gated Channel Subfamily C Member 1 Activator, Purinergic Receptor P2X Antagonist, Purinergic Receptor P2Y Antagonist, Sigma Non Opioid Intracellular Receptor 1 Agonist, Synaptic Functional Regulator FMR1 Activator, and others.
-
What are the key routes of administration in the Fragile X Syndrome pipeline products market?
The key routes of administration in the Fragile X Syndrome pipeline products market are oral, intravenous, intrathecal, nasal, parenteral, and transdermal.
-
What are the key molecule types in the Fragile X Syndrome pipeline products market?
The key molecule types in the Fragile X Syndrome pipeline products market are small molecule, gene therapy, antisense oligonucleotide, recombinant peptide, and synthetic peptide.
-
Which are the major companies in the Fragile X Syndrome pipeline products market?
Some of the major companies in the Fragile X Syndrome pipeline products market are Connecta Therapeutics SL, Healx Ltd, Autifony Therapeutics Ltd, Confluence Pharmaceuticals LLC, Epigen Biosciences Inc, Neuren Pharmaceuticals Ltd, Paxmedica Inc, RespireRx Pharmaceuticals Inc, Actinogen Medical Ltd, and Allos Pharma Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.